贝伐珠单抗联合以紫杉醇+顺铂为基础的同步放化疗治疗子宫颈癌的临床疗效

doi:10.3969/j.issn.1671-7171.2024.08.021

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1187 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨贝伐珠单抗联合以紫杉醇+顺铂(TP)为基础的同步放化疗治疗子宫颈癌的疗效。【方法】选择2021年12月至2023年1月本院收治的90例子宫颈癌患者,按照随机数字表法分为观察组和对照组,每组45例。对照组采用TP同步放化疗,观察组在对照组的基础上采用贝伐珠单抗治疗,21 d为1个治疗周期,均治疗3个周期。比较两组临床疗效、血清学指标、免疫功能指标、生活质量评分、不良反应发生率。【结果】观察组临床缓解率(55.56%)高于对照组(33.33%)(P<0.05)。治疗后,两组血清糖类抗原125(CA125)、鳞状细胞癌抗原(SCC)、转化生长因子β1(TGF-β1)水平均降低(P<0.05),且观察组上述指标低于对照组(P<0.05)。治疗后,观察组CD3⁺、CD4⁺高于对照组(P<0.05),CD8⁺低于对照组(P<0.05)。治疗后,两组癌症治疗功能评价量表(FACT-G)评分均升高(P<0.05),且观察组FACT-G评分高于对照组(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。【结论】贝伐珠单抗联合以TP为基础的同步放化疗治疗子宫颈癌患者疗效确切,可改善患者免疫功能及生活质量,降低患者肿瘤标志物和TGF-β1表达水平,且安全性较好,值得临床推广应用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：宫颈肿瘤/药物疗法, 宫颈肿瘤/放射疗法, 抗体,单克隆/治疗应用, 紫杉醇/治疗应用

Abstract：【Objective】To investigate the efficacy of bevacizumab combined with paclitaxel+cisplatin (TP) based synchronous radiochemotherapy in the treatment of cervical cancer. 【Methods】Ninety cervical cancer patients admitted to our hospital from December 2021 to January 2023 were selected and randomly divided into the observation group and the control group using a random number table method, with 45 patients in each group. The control group was treated with TP synchronous radiotherapy and chemotherapy, while the observation group was treated with bevacizumab on the basis of the control group. One treatment cycle was 21 days, and both groups were treated for three cycles. Two groups were compared in terms of clinical efficacy, serological indicators, immune function indicators, quality of life scores, and incidence of adverse reactions. 【Results】The clinical remission rate of the observation group (55.56%) was higher than that of the control group (33.33%) (P<0.05). After treatment, the levels of serum carbohydrate antigen 125 (CA125), squamous cell carcinoma antigen (SCC), and transforming growth factor beta 1 (TGF-β1) decreased in both groups (P<0.05), and the above indicators in the observation group were lower than those in the control group (P<0.05). After treatment, the observation group had higher levels of CD3⁺ and CD4⁺ than the control group (P<0.05), and lower levels of CD8⁺ than the control group (P<0.05). After treatment, the FACT-G scores of both groups of cancer treatment function evaluation scales increased (P<0.05), and the FACT-G score of the observation group was higher than that of the control group (P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】 The combination of bevacizumab and TP based synchronous chemoradiotherapy is effective in treating cervical cancer patients, improving their immune function and quality of life, reducing tumor markers and TGF-β1 expression levels, and has good safety. It is worthy of clinical application.

Key words： Uterine Cervical Neoplasms/DT Uterine Cervical Neoplasms/RT Antibodies, Monoclonal/TU Taxol/TU

收稿日期: 2023-12-15

中图分类号:

R711.74

通讯作者: * E-mail:249256894@qq.com

引用本文:

杨新华, 宋庆, 司志刚, 冯艳亮, 郭亚敏. 贝伐珠单抗联合以紫杉醇+顺铂为基础的同步放化疗治疗子宫颈癌的临床疗效[J]. 医学临床研究, 2024, 41(8): 1191-1194.
YANG Xinhua, SONG Qing, SI Zhigang, et al. Clinical Efficacy of Bevacizumab Combined with Paclitaxel and Cisplatin Based Synchronous Radiochemotherapy in the Treatment of Cervical Cancer. JOURNAL OF CLINICAL RESEARCH, 2024, 41(8): 1191-1194.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.08.021 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I8/1191